4D Molecular Therapeutics(FDMT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 EMERYVILLE, Calif., May 8, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones. 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights an ...